Neurogene (NGNE) Cash from Investing Activities (2013 - 2026)

Neurogene has reported Cash from Investing Activities for 14 years, with the latest figure at $46.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Investing Activities rose 202.65% year-over-year to $46.2 million; the trailing twelve-month figure through Mar 2026 stood at $105.3 million (up 152.58% YoY), and the FY2025 full-year result was $14.0 million, up 111.18% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $46.2 million, up from $29.6 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $65.4 million in Q4 2022, with the low at -$102.6 million in Q4 2024.
• Historically, Cash from Investing Activities has averaged -$2.4 million across 5 years, with a median of -$82000.0 in 2023.
• The largest YoY upside for Cash from Investing Activities was 103324.14% in 2024 against a maximum downside of 35224.39% in 2024.
• Neurogene's Cash from Investing Activities stood at $65.4 million in 2022, then plunged by 60.49% to $25.8 million in 2023, then sank by 497.27% to -$102.6 million in 2024, then surged by 128.85% to $29.6 million in 2025, then soared by 56.17% to $46.2 million in 2026.
• The last three Cash from Investing Activities figures came in at $46.2 million (Q1 2026), $29.6 million (Q4 2025), and $22.0 million (Q3 2025), per Business Quant data.